🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

AbbVie Inc. ABBV SPXR3KPHARMA

Healthcare · Drug Manufacturers - General · United States
https://www.abbvie.com
Company Profile ↓
$285.19
+45.95% 1Y
Mkt Cap$503.96B
P/E80.56
P/B-82.31
Div. Yield2.54%
52W High$289.08
52W Low$194.79
Book Value$-3.36
EPS (TTM)$3.54

Company Overview

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Why Investors Should Care

Healthy Margins

Operating margin of 40.0% supports profitability.

Dividend Income

Offers a dividend yield of 2.54%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $61.16B (+8.6% YoY); net profit $4.23B.
  • Trailing 12 Months Year-on-year growth — revenue +10.2%, earnings +290.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 1.8%, profit CAGR -29.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:1.75%
1 Year:10.20%

Compounded Profit Growth

5 Years:-29.06%
1 Year:290.40%

Stock Price Performance

1 Year:+45.95%
6 Months:+43.81%
3 Months:+10.63%
1 Month:+8.25%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 96% of range
$194.79 $289.08
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)65.75 · Neutral
Price Performance
1M+8.25%
3M+10.63%
6M+43.81%
1Y+45.95%
Valuation vs Sector

P/E of 80.56 is above the sector median of 25.61 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Attractive dividend yield of 2.54%.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 80.6.
  • Earnings shrank at -29.1% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
80.56
Industry PE
25.61
Forward P/E
17.54
PEG Ratio
0.55
Book Value
$-3.36
Price to Book
-82.31
P/S
7.59
EV/EBITDA
17.68
Dividend Yield
2.54%

Growth (CAGR)

Revenue 5Y
1.75%
Profit 5Y
-29.06%
Revenue (YoY)
10.20%
Earnings (YoY)
290.40%

Profitability & Returns

ROCE
10.47%
ROE
-129.24%
ROA
10.51%
Profit Margin
9.80%
Op Margin
40.03%
Gross Margin
72.79%
EPS (Latest Qtr)
$2.03
EPS (TTM)
$3.54

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
0.49
Current Ratio
0.81
Debt
$70.88B
Total Assets
$135.12B
Current Assets
$33.53B
Working Capital
$-14.23B

Ownership

Promoter Holding
0.11%
Chg in Prom Hold
0.00%
FII / Inst Holding
77.33%
Chg in FII Hold
-0.04%

Financial Snapshot

Enterprise Value
$503.96B
Total Revenue (TTM)
$64.39B
EBITDA
$30.76B
Free Cash Flow
$16.87B
Operating Cash Flow
$19.51B
Shares Outstanding
1.77B
Gross Margin
72.79%
Payout Ratio
190.40%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ABBV AbbVie Inc. SPXR3KPHARMA 285.19 80.56 $503.96B 2.54% 10.47% -129.24% 1.75% -29.06%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,306.69 43.95 $1.16T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 267.61 31.05 $644.91B 1.98% 14.88% 25.74% 2.43% 4.76%
4 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 424.98 27.29 $381.46B 2.47% 9.74% 14.15% 10.40% 5.43%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 147.24 117.79 $363.27B 2.31% - 6.96% 5.64% 10.01%
6 NVS Novartis AG PHARMA 156.27 23.61 $297.02B 3.36% 21.09% 30.35% 9.25% 26.22%
7 AZN AstraZeneca PLC NDXPHARMA 172.57 25.80 $267.64B 2.00% 15.97% 21.96% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 676.54 36.45 $250.15B 0.29% 8.14% 13.51% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 447.28 27.78 $241.81B 2.44% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue --6.54B6.94B7.00B-7.93B8.28B8.24B-------------------------13.34B15.42B15.78B16.62B15.00B-
Cost of Revenue ----------------------------------4.00B4.35B5.30B4.55B4.22B-
Gross Profit 4.93B5.24B4.92B5.42B5.38B5.46B6.01B6.34B6.40B6.28B6.13B6.44B6.56B6.70B---9.17B---10.57B---10.95B---8.60B----9.34B11.08B10.47B12.07B10.78B-
Operating Expenses ----------------------------------5.36B5.36B5.89B6.26B6.05B-
Operating Income 2.36B-2.41B2.66B2.69B-2.90B2.76B3.16B-3.01B3.40B2.62B-3.60B752.00M3.25B-4.10B4.44B4.31B-4.72B3.29B4.60B-2.77B4.51B2.28B-2.80B4.00B3.83B-3.98B5.72B4.58B5.81B4.73B6.43B
EBITDA ----------------------------------4.40B4.34B3.52B5.37B3.69B-
Interest Expense ----------------------------------700.00M740.00M739.00M714.00M717.00M-
Pretax Income ----------------------------------1.66B1.55B714.00M2.67B1.04B-
Tax Provision ----------------------------------372.00M613.00M526.00M853.00M342.00M-
Net Income 1.60B1.39B1.71B1.92B1.63B52.00M2.78B1.98B2.75B-1.83B2.46B741.00M1.88B2.80B3.01B-738.00M2.31B36.00M3.55B766.00M3.18B4.04B4.49B924.00M3.95B2.47B239.00M2.02B1.78B822.00M1.37B1.37B1.56B-1.29B938.00M186.00M1.82B695.00M3.61B
Diluted EPS 0.970.851.061.191.010.031.741.261.81-1.231.650.491.261.882.02-0.461.290.011.990.421.782.262.510.512.211.380.131.141.000.460.770.770.88-0.720.520.101.020.392.03

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 17.44B18.38B18.79B19.96B22.86B25.64B28.22B32.75B33.27B45.80B56.20B58.05B54.32B56.33B61.16B
Cost of Revenue -----------17.41B20.41B16.90B18.20B
Gross Profit -----------40.64B33.90B39.43B42.96B
Operating Expenses -----------21.83B20.37B27.54B22.86B
Operating Income 3.62B5.82B5.66B3.41B7.54B9.34B9.54B6.38B12.98B11.36B17.92B18.81B13.54B11.89B20.09B
EBITDA -----------24.17B17.17B14.91B17.63B
Interest Expense -----------2.23B2.22B2.81B2.89B
Pretax Income -----------13.48B6.25B3.72B6.60B
Tax Provision -----------1.63B1.38B-570.00M2.36B
Net Income 3.43B5.28B4.13B1.77B5.14B5.95B5.31B5.69B7.88B4.62B11.54B11.84B4.86B4.28B4.23B
Diluted EPS 2.183.352.561.103.133.633.303.665.282.726.456.632.722.392.36

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --27.01B29.20B27.51B53.05B66.10B70.79B59.35B89.11B150.56B-138.81B134.71B135.16B133.96B
Current Assets ------------28.46B33.00B25.58B29.06B
Cash & Equivalents 10.00M27.00M5.90B9.60B8.35B8.40B5.10B9.30B7.29B39.92B8.45B-9.20B12.81B5.52B5.23B
Inventory ------------3.58B4.10B4.18B4.95B
Receivables ------------11.25B11.15B10.92B12.59B
Total Liabilities ------------121.52B124.31B131.80B137.19B
Current Liabilities --6.78B6.88B11.39B10.89B9.78B16.64B17.24B15.59B28.66B-29.54B37.84B38.75B43.29B
Long Term Debt ---------67.23B84.95B-59.13B52.19B60.34B58.94B
Total Debt ------------63.27B59.38B67.14B67.50B
Total Equity ---350.00M4.49B1.74B3.94B4.64B5.10B-8.45B-8.17B13.08B-17.25B10.36B3.33B-3.27B
Shares Outstanding ------------1.81B1.82B1.83B1.84B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ------9.96B13.43B13.32B17.59B-24.94B22.84B18.81B19.03B
Investing Cash Flow -------274.00M-1.01B596.00M-37.56B--623.00M-2.01B-20.82B-6.64B
Financing Cash Flow ------3.93B-5.51B-14.40B18.71B-11.50B--24.80B-17.22B-5.21B-12.72B
Capital Expenditure -356.00M-333.00M-491.00M-612.00M-532.00M-479.00M-529.00M-638.00M-552.00M-798.00M--695.00M-777.00M-974.00M-1.21B
Free Cash Flow ------9.43B12.79B12.77B16.79B-24.25B22.06B17.83B17.82B
Net Change in Cash ------------483.00M3.61B-7.22B-337.00M
Share Buybacks --320.00M665.00M7.59B6.03B1.41B12.01B629.00M978.00M934.00M1.49B1.97B1.71B980.00M
Dividends Paid --2.56B2.66B3.29B3.72B4.11B5.58B6.37B7.72B9.26B10.04B10.54B11.03B11.66B

Ratios (Annual)

Figures in %.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------70.0%62.4%70.0%70.2%
Operating Margin % 20.8%31.6%30.1%17.1%33.0%36.4%33.8%19.5%39.0%24.8%31.9%32.4%24.9%21.1%32.8%
Net Margin % 19.7%28.7%22.0%8.9%22.5%23.2%18.8%17.4%23.7%10.1%20.5%20.4%9.0%7.6%6.9%
ROE % --1,507.1%91.9%101.8%130.4%128.4%104.2%-67.3%-96.5%35.3%-68.6%46.9%128.7%-129.2%
ROCE % -28.8%25.4%21.2%17.9%16.6%17.6%15.2%17.7%9.3%-17.2%14.0%12.3%22.2%

Shareholding Pattern

Insiders
0.11%
Institutions
77.33%
Public Float
77.42%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.46% 149.49M $41.33B
2 Vanguard Capital Management LLC 6.53% 115.40M $31.90B
3 State Street Corporation 4.67% 82.60M $22.84B
4 Vanguard Portfolio Management LLC 2.74% 48.48M $13.40B
5 JPMORGAN CHASE & CO 2.71% 47.86M $13.23B
6 Geode Capital Management, LLC 2.66% 47.00M $12.99B
7 Morgan Stanley 2.20% 38.90M $10.75B
8 Capital Research Global Investors 1.70% 30.10M $8.32B
9 NORGES BANK 1.45% 25.55M $7.07B
10 Bank of America Corporation 1.20% 21.24M $5.87B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ABBV

Yahoo Finance hu, 22 Oct 2026

Great News for AbbVie Stock Investors

The company is gearing up for future major patent cliffs.

Yahoo Finance hu, 22 Oct 2026

MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”

Key TakeawaysMoonLake shares jumped 18% today after AbbVie reported Phase 3 results for a rival hidradenitis suppurativa drug. AbbVie’s lutikizumab beat placebo by 8 percentage points on its main goal, a result RBC Capital called underwhelm…

Yahoo Finance hu, 22 Oct 2026

Avalo Therapeutics Abdakibart Potential Intact After AbbVie Data, Wedbush Says

Avalo Therapeutics' (AVTX) abdakibart remains promising for hidradenitis suppurativa, with phase 2 r

Yahoo Finance hu, 22 Oct 2026

Jim Cramer and Ken Fisher Like This Healthcare Stock

With AI stocks making waves, some prudent investors are looking at healthcare names to diversify amid concerns about an AI data center slowdown. AbbVie Inc. (NYSE:ABBV) ranks eighth on our list of the top 10 stocks Jim Cramer and billionair…

Yahoo Finance hu, 22 Oct 2026

AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa

AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab, an investigational dual-variable-domain interleukin (IL) 1α/1β antagonist, in adults and adolesc…

Yahoo Finance hu, 22 Oct 2026

AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?

The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buyin…

ABBV — Frequently Asked Questions

What is the current share price of AbbVie Inc. (ABBV)?

As of 2026-10-22 16:30 PDT, AbbVie Inc. (ABBV) trades at $285.19 on NYSE. Its 52-week range is $194.79 to $289.08.

What is the market capitalisation of ABBV?

AbbVie Inc. (ABBV) has a market capitalisation of $503.96B on NYSE.

What is the P/E ratio of ABBV?

ABBV trades at a trailing price-to-earnings (P/E) ratio of 80.56. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is -82.31.

Does ABBV pay a dividend?

AbbVie Inc. (ABBV) currently offers a dividend yield of 2.54%.

What is the return on equity (ROE) of ABBV?

ABBV has a return on equity (ROE) of -129.24%. Its return on capital employed (ROCE) is 10.47%.

Is ABBV a good stock to buy?

This page provides a data-driven analysis of AbbVie Inc. (ABBV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space